BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20168282)

  • 1. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
    Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of NETs with PET radiopharmaceuticals.
    Ambrosini V; Tomassetti P; Franchi R; Fanti S
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary nuclear medicine imaging of neuroendocrine tumours.
    Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
    Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
    Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on nuclear medicine imaging of neuroendocrine tumors.
    Goldsmith SJ
    Future Oncol; 2009 Feb; 5(1):75-84. PubMed ID: 19243300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear medicine imaging of neuroendocrine tumours.
    Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
    Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostics of neuroendocrine tumours.
    Hodolic M; Fettich J; Banti E; Chondrogiannis S; Al-Nahhas A; Rubello D
    In Vivo; 2010; 24(5):771-4. PubMed ID: 20952747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Bal CS; Gupta SK; Zaknun JJ
    Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
    Kjaer A; Knigge U
    Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
    Pepe G; Bombardieri E; Lorenzoni A; Chiti A
    PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
    Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
    Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
    Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
    Johnbeck CB; Knigge U; Kjær A
    Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.